Nicola E Owen1, Duuamene Nyimanu1, Rhoda E Kuc1, Paul D Upton2, Nicholas W Morrell2, Graeme J Alexander3, Janet J Maguire1, Anthony P Davenport4. 1. Experimental Medicine and Immunotherapeutics, University of Cambridge, Level 6, Centre for Clinical Investigation, Box 110, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK. 2. Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK. 3. Institute for Liver and Digestive Health, Upper 3rd Floor, Division of Medicine, University College London, Royal Free Campus, Rowland Hill Street, London, NW3 2PF, UK. 4. Experimental Medicine and Immunotherapeutics, University of Cambridge, Level 6, Centre for Clinical Investigation, Box 110, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK. Electronic address: apd10@medschl.cam.ac.uk.
Abstract
BACKGROUND: The peptide apelin is expressed in human healthy livers and is implicated in the development of hepatic fibrosis and cirrhosis. Mutations in the bone morphogenetic protein receptor type II (BMPR-II) result in reduced plasma levels of apelin in patients with heritable pulmonary arterial hypertension. Ligands for BMPR-II include bone morphogenetic protein 9 (BMP9), highly expressed in liver, and BMP10, expressed in heart and to a lesser extent liver. However, it is not known whether reductions in BMP9 and/or BMP10, with associated reduction in BMPR-II signalling, correlate with altered levels of apelin in patients with liver fibrosis and cirrhosis. METHODS: Plasma from patients with liver fibrosis (n = 14), cirrhosis (n = 56), and healthy controls (n = 25) was solid-phase extracted using a method optimised for recovery of apelin, which was measured by ELISA. RESULTS: Plasma apelin was significantly reduced in liver fibrosis (8.3 ± 1.2 pg/ml) and cirrhosis (6.5 ± 0.6 pg/ml) patients compared with controls (15.4 ± 2.0 pg/ml). There was no obvious relationship between apelin and BMP 9 or BMP10 previously measured in these patients. Within the cirrhotic group, there was no significant correlation between apelin levels and disease severity scores, age, sex, or treatment with β-blockers. CONCLUSIONS: Apelin was significantly reduced in plasma of patients with both early (fibrosis) and late-stage (cirrhosis) liver disease. Fibrosis is more easily reversible and may represent a potential target for new therapeutic interventions. However, it remains unclear whether apelin signalling is detrimental in liver disease or is beneficial and therefore, whether an apelin antagonist or agonist have clinical use.
BACKGROUND: The peptide apelin is expressed in human healthy livers and is implicated in the development of hepatic fibrosis and cirrhosis. Mutations in the bone morphogenetic protein receptor type II (BMPR-II) result in reduced plasma levels of apelin in patients with heritable pulmonary arterial hypertension. Ligands for BMPR-II include bone morphogenetic protein 9 (BMP9), highly expressed in liver, and BMP10, expressed in heart and to a lesser extent liver. However, it is not known whether reductions in BMP9 and/or BMP10, with associated reduction in BMPR-II signalling, correlate with altered levels of apelin in patients with liver fibrosis and cirrhosis. METHODS: Plasma from patients with liver fibrosis (n = 14), cirrhosis (n = 56), and healthy controls (n = 25) was solid-phase extracted using a method optimised for recovery of apelin, which was measured by ELISA. RESULTS: Plasma apelin was significantly reduced in liver fibrosis (8.3 ± 1.2 pg/ml) and cirrhosis (6.5 ± 0.6 pg/ml) patients compared with controls (15.4 ± 2.0 pg/ml). There was no obvious relationship between apelin and BMP 9 or BMP10 previously measured in these patients. Within the cirrhotic group, there was no significant correlation between apelin levels and disease severity scores, age, sex, or treatment with β-blockers. CONCLUSIONS: Apelin was significantly reduced in plasma of patients with both early (fibrosis) and late-stage (cirrhosis) liver disease. Fibrosis is more easily reversible and may represent a potential target for new therapeutic interventions. However, it remains unclear whether apelin signalling is detrimental in liver disease or is beneficial and therefore, whether an apelin antagonist or agonist have clinical use.
Authors: Pedro Melgar-Lesmes; Montserrat Pauta; Vedrana Reichenbach; Gregori Casals; Josefa Ros; Ramon Bataller; Manuel Morales-Ruiz; Wladimiro Jiménez Journal: Gut Date: 2011-03-29 Impact factor: 23.059
Authors: A P Davenport; M J Ashby; P Easton; S Ella; J Bedford; C Dickerson; D J Nunez; S J Capper; M J Brown Journal: Clin Sci (Lond) Date: 1990-03 Impact factor: 6.124
Authors: Aimee L Brame; Janet J Maguire; Peiran Yang; Alex Dyson; Rubben Torella; Joseph Cheriyan; Mervyn Singer; Robert C Glen; Ian B Wilkinson; Anthony P Davenport Journal: Hypertension Date: 2015-02-23 Impact factor: 10.190
Authors: Peiran Yang; Rhoda E Kuc; Aimée L Brame; Alex Dyson; Mervyn Singer; Robert C Glen; Joseph Cheriyan; Ian B Wilkinson; Anthony P Davenport; Janet J Maguire Journal: Front Neurosci Date: 2017-02-28 Impact factor: 4.677
Authors: Elizabeth Harford-Wright; Gwennan Andre-Gregoire; Kathryn A Jacobs; Lucas Treps; Sophie Le Gonidec; Heloise M Leclair; Sara Gonzalez-Diest; Quentin Roux; François Guillonneau; Delphine Loussouarn; Lisa Oliver; François M Vallette; Fabienne Foufelle; Philippe Valet; Anthony P Davenport; Robert C Glen; Nicolas Bidere; Julie Gavard Journal: Brain Date: 2017-11-01 Impact factor: 13.501
Authors: Philipp Wolf; Alexander Mohr; Georgina Gavins; Victoria Behr; Karin Mörl; Oliver Seitz; Annette G Beck-Sickinger Journal: Chembiochem Date: 2021-10-26 Impact factor: 3.461